Ocular Therapeutix (NSDQ:OCUL) said today that it inked a deal with an investor to issue $37.5 million in 6% subordinated convertible notes due 2026. The offering is slated to close on March 1, according to the Bedford, Mass.-based company.
Ocular expects to reel in roughly $37.1 million in net proceeds from the offering, which it plans to use to fund the launch of Dextenza and support its late-stage pipeline.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.